Cite this article
10
Downloads
2
Citations
52
Views
Announcements
Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Original Research
Very unusual symptoms consistent with a possible migraine immediately following the injection of recombinant follitropin beta
J. H. Check1,2,*
Show Less
1
Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Camden, NJ
2
Cooper Institute for Reproductive Hormonal Disorders, P.C. Mt. Laurel, NJ (USA)
Clin. Exp. Obstet. Gynecol. 2016, 43(4), 484–485;
https://doi.org/10.12891/ceog3233.2016
Published: 10 August 2016
Abstract
Purpose: To present a new side effect of follitropin beta not shared with highly purified urinary follicle stimulating hormone (FSH). Materials and Methods: Follitropin beta was administered for preparation of in vitro fertilization-embryo transfer (IVF-ET). Results: Within a few minutes of injection of subcutaneously of follitropin beta, a 27-year-old woman developed a feeling of fever, headache, nausea, vomiting dizziness, and a visual aura consistent with migraine syndrome. These side effects did not occur when switched to highly purified urinary FSH. Conclusions: Since this reaction did not occur when injected with FSH not made with recombinant DNA technology, it is concluded that recombinant FSH (at least with follitropin beta) can produce an immediate migraine-like syndrome.
Keywords
Recombinant FSH
Follitropin beta
Migraine headaches
High purified urinary FSH